Why the study?
Does YM866 improve recanalization compared to tPA in a canine model of femoral arterial thrombosis?
Does YM866 improve recanalization compared to tPA in a canine model of femoral arterial thrombosis?
A mutant tPA (YM866) administered as an intravenous bolus at a lower dose provides equivalent thrombolytic efficacy to standard tPA infusion in a canine thrombosis model.
Answers are grounded in this paper and cite their sources.
Bolus YM866 matches tPA infusion efficacy in canine thrombosis; leaves open translation to human thrombolysis trials.
Because tissue-type plasminogen activator (tPA), used to treat myocardial infarction, has several disadvantages thought to be connected with its low half-life, mutants of tPA have been prepared with longer half-lives. We have compared the thrombolytic effect of such a mutant, YM866, with that of tPA in copper-coil-induced femoral arterial thrombosis in dogs. One hour after thrombus formation, YM866 was administered by intravenous bolus injection, while tPA was given by the same method or by 60-min infusion under adequate heparinization. Both agents exhibited dose-dependent thrombolysis without systemic fibrinogenolysis. The recanalization rate and recanalization time of YM866 by bolus at 0.2 mg kg-1 were, however, equivalent to those of tPA by infusion at 0.4 mg kg-1 (total dose), whereas the recanalization rate of tPA by bolus was low (0.4 mg kg-1). No significant difference in reocclusion rate, reocclusion time, or patency status after successful thrombolysis was seen. These results suggest that YM866 administered at a lower dose by intravenous bolus injection exerted a thrombolytic effect equivalent to that of tPA by infusion, and that heparin could not prevent reocclusion after successful thrombolysis even under adequate anticoagulation.
No takes yet. Share an insight, caveat, or question.
Kawasaki et al. (1996) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: